Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN NASDAQ:MACK NASDAQ:MYGN NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.27-3.8%$1.33$1.09▼$4.83$842.18M0.636.18 million shs4.25 million shsMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/AMYGNMyriad Genetics$7.24-5.7%$5.58$3.76▼$29.30$714.58M1.931.31 million shs2.00 million shsRIGLRigel Pharmaceuticals$37.96+0.4%$30.15$13.01▼$43.72$678.38M1.27749,294 shs379,731 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron-3.79%-9.29%-11.19%-15.89%-71.07%MACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MYGNMyriad Genetics-5.73%+9.53%+23.34%+43.94%-72.45%RIGLRigel Pharmaceuticals+0.37%-8.18%+3.77%+84.99%+192.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.27-3.8%$1.33$1.09▼$4.83$842.18M0.636.18 million shs4.25 million shsMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/AMYGNMyriad Genetics$7.24-5.7%$5.58$3.76▼$29.30$714.58M1.931.31 million shs2.00 million shsRIGLRigel Pharmaceuticals$37.96+0.4%$30.15$13.01▼$43.72$678.38M1.27749,294 shs379,731 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron-3.79%-9.29%-11.19%-15.89%-71.07%MACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MYGNMyriad Genetics-5.73%+9.53%+23.34%+43.94%-72.45%RIGLRigel Pharmaceuticals+0.37%-8.18%+3.77%+84.99%+192.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.29Hold$3.79198.09% UpsideMACKMerrimack Pharmaceuticals 0.00N/AN/AN/AMYGNMyriad Genetics 2.21Hold$12.4572.02% UpsideRIGLRigel Pharmaceuticals 2.40Hold$38.200.63% UpsideCurrent Analyst Ratings BreakdownLatest MACK, GERN, MYGN, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.007/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$1.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$76.99M10.52N/AN/A$0.46 per share2.76MACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMYGNMyriad Genetics$837.60M0.80$0.94 per share7.69$7.70 per share0.94RIGLRigel Pharmaceuticals$267.92M2.54$1.08 per share35.06$0.19 per share199.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)MACKMerrimack Pharmaceuticals-$1.18M$13.871.09∞N/AN/A-1.93%-1.78%N/AMYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$5.417.0236.15N/A36.51%438.89%57.03%11/6/2025 (Estimated)Latest MACK, GERN, MYGN, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.467.876.79MACKMerrimack PharmaceuticalsN/A10.7810.78MYGNMyriad GeneticsN/A1.421.28RIGLRigel Pharmaceuticals0.462.021.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%MACKMerrimack Pharmaceuticals63.97%MYGNMyriad Genetics99.02%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipGERNGeron7.42%MACKMerrimack Pharmaceuticals30.57%MYGNMyriad Genetics2.40%RIGLRigel Pharmaceuticals9.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70638.02 million590.68 millionOptionableMACKMerrimack Pharmaceuticals42614.79 million10.27 millionOptionableMYGNMyriad Genetics2,70093.04 million90.81 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableMACK, GERN, MYGN, and RIGL HeadlinesRecent News About These CompaniesDynamic Technology Lab Private Ltd Acquires Shares of 27,117 Rigel Pharmaceuticals, Inc. $RIGL2 hours ago | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Down 6.1% - Here's What HappenedSeptember 11 at 2:28 PM | marketbeat.comCan Tavalisse Drive Rigel's Growth Through the Rest of 2025?September 11 at 10:51 AM | zacks.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Drop in Short InterestSeptember 11 at 6:12 AM | marketbeat.comJacobs Levy Equity Management Inc. Grows Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 11 at 4:08 AM | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by AnalystsSeptember 11 at 2:39 AM | marketbeat.comWhat Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comA Look At The Intrinsic Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)September 9, 2025 | uk.finance.yahoo.comTrexquant Investment LP Lowers Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 9, 2025 | marketbeat.comDo Options Traders Know Something About RIGL Stock We Don't?September 6, 2025 | msn.comRafferty Asset Management LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGLSeptember 5, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 11,070 Shares of Rigel Pharmaceuticals, Inc. $RIGLSeptember 3, 2025 | marketbeat.comArmistice Capital LLC Has $27.27 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 2, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. $RIGL Shares Bought by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.com115,218 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Nuveen LLCSeptember 1, 2025 | marketbeat.comInvesco Ltd. Purchases Shares of 134,072 Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comVanguard Group Inc. Has $18.50 Million Stake in Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comRigel to Participate in Upcoming September Investor ConferencesAugust 26, 2025 | prnewswire.comThis ‘Darling’ Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out SoonAugust 25, 2025 | finance.yahoo.comThis ‘Darling’ Pharma Stock Is Hitting New HighsAugust 25, 2025 | barchart.comRigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?August 25, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMACK, GERN, MYGN, and RIGL Company DescriptionsGeron NASDAQ:GERN$1.27 -0.05 (-3.79%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.29 +0.02 (+1.50%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Merrimack Pharmaceuticals NASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Myriad Genetics NASDAQ:MYGN$7.24 -0.44 (-5.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.36 +0.13 (+1.73%) As of 09/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Rigel Pharmaceuticals NASDAQ:RIGL$37.96 +0.14 (+0.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$38.00 +0.04 (+0.11%) As of 09/12/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
